{"title":"超声青光眼成形术治疗难治性青光眼的疗效。","authors":"Hui-Min Zhong, Xiao-Hong Liu, Shou-Yue Huang, Hui-Ping Yao, Yi-Sheng Zhong, Jing Wang","doi":"10.18240/ijo.2025.03.08","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the efficacy and safety of ultrasound cyclo-plasty (UCP) in lowering intraocular pressure (IOP) among Chinese patients suffering from refractory glaucoma.</p><p><strong>Methods: </strong>In this 12-month retrospective study, 28 patients with refractory glaucoma (IOP≥25 mm Hg) were treated with 8-second UCP using either 8 or 10 probe sectors. The principal measure of efficacy was the decrease in IOP at the following intervals after UCP: 1d, 1, 3, 6, and 12mo, with each measurement compared to baseline.</p><p><strong>Results: </strong>Mean IOP (in mm Hg) was reduced from 46.8±8.9 to 24.5±3.2, 27.0±4.8, 29.1±4.6, 26.1±4.5, and 28.3±4.8 at 1d, 1, 3, 6, and 12mo postoperatively, respectively. Compared to baseline, IOP reductions at these time points were 45.0%, 39.9%, 35.3%, 41.4%, and 36.7%, respectively. Most patients experienced relief from ocular pain after surgery. No cases of choroidal detachment or hypotony was observed.</p><p><strong>Conclusion: </strong>UCP is effective in reducing IOP among Chinese patients with refractory glaucoma and shows a favorable safety profile.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 3","pages":"420-423"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865642/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of ultrasound cyclo-plasty in patients with refractory glaucoma.\",\"authors\":\"Hui-Min Zhong, Xiao-Hong Liu, Shou-Yue Huang, Hui-Ping Yao, Yi-Sheng Zhong, Jing Wang\",\"doi\":\"10.18240/ijo.2025.03.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To assess the efficacy and safety of ultrasound cyclo-plasty (UCP) in lowering intraocular pressure (IOP) among Chinese patients suffering from refractory glaucoma.</p><p><strong>Methods: </strong>In this 12-month retrospective study, 28 patients with refractory glaucoma (IOP≥25 mm Hg) were treated with 8-second UCP using either 8 or 10 probe sectors. The principal measure of efficacy was the decrease in IOP at the following intervals after UCP: 1d, 1, 3, 6, and 12mo, with each measurement compared to baseline.</p><p><strong>Results: </strong>Mean IOP (in mm Hg) was reduced from 46.8±8.9 to 24.5±3.2, 27.0±4.8, 29.1±4.6, 26.1±4.5, and 28.3±4.8 at 1d, 1, 3, 6, and 12mo postoperatively, respectively. Compared to baseline, IOP reductions at these time points were 45.0%, 39.9%, 35.3%, 41.4%, and 36.7%, respectively. Most patients experienced relief from ocular pain after surgery. No cases of choroidal detachment or hypotony was observed.</p><p><strong>Conclusion: </strong>UCP is effective in reducing IOP among Chinese patients with refractory glaucoma and shows a favorable safety profile.</p>\",\"PeriodicalId\":14312,\"journal\":{\"name\":\"International journal of ophthalmology\",\"volume\":\"18 3\",\"pages\":\"420-423\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865642/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18240/ijo.2025.03.08\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.03.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：评价超声睫状体成形术（UCP）降低中国难治性青光眼患者眼压（IOP）的疗效和安全性。方法：在这项为期12个月的回顾性研究中，28例难治性青光眼（IOP≥25 mm Hg）患者使用8或10个探针段进行8秒UCP治疗。疗效的主要测量是在UCP后的以下时间间隔内IOP的下降：1d， 1,3,6和12个月，每次测量与基线相比。结果：术后1d、1、3、6、12月平均IOP （mm Hg）分别由46.8±8.9降至24.5±3.2、27.0±4.8、29.1±4.6、26.1±4.5、28.3±4.8。与基线相比，这些时间点的IOP降低分别为45.0%、39.9%、35.3%、41.4%和36.7%。大多数患者术后眼痛得到缓解。无一例脉络膜脱离或低斜视。结论：UCP可有效降低中国难治性青光眼患者的IOP，且具有良好的安全性。
Efficacy of ultrasound cyclo-plasty in patients with refractory glaucoma.
Aim: To assess the efficacy and safety of ultrasound cyclo-plasty (UCP) in lowering intraocular pressure (IOP) among Chinese patients suffering from refractory glaucoma.
Methods: In this 12-month retrospective study, 28 patients with refractory glaucoma (IOP≥25 mm Hg) were treated with 8-second UCP using either 8 or 10 probe sectors. The principal measure of efficacy was the decrease in IOP at the following intervals after UCP: 1d, 1, 3, 6, and 12mo, with each measurement compared to baseline.
Results: Mean IOP (in mm Hg) was reduced from 46.8±8.9 to 24.5±3.2, 27.0±4.8, 29.1±4.6, 26.1±4.5, and 28.3±4.8 at 1d, 1, 3, 6, and 12mo postoperatively, respectively. Compared to baseline, IOP reductions at these time points were 45.0%, 39.9%, 35.3%, 41.4%, and 36.7%, respectively. Most patients experienced relief from ocular pain after surgery. No cases of choroidal detachment or hypotony was observed.
Conclusion: UCP is effective in reducing IOP among Chinese patients with refractory glaucoma and shows a favorable safety profile.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
